MNMD
Mind Medicine (MindMed) Inc.
$20.69
+0.09
(+0.44%)
Mkt Cap
1.56B
Volume
298,406
52W Range
4.7-21.08
Sector
Healthcare
Beta
2.62
EPS (TTM)
-2.50
P/E Ratio
-6.51
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (183.79M) | (108.68M) | (95.73M) | (56.80M) | (93.04M) | (34.10M) | (1.12M) | (857,944) | (1.23M) | (179,900) | (92,656) |
| EPS | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Free Cash Flow | (131.56M) | (79.13M) | (64.36M) | (50.14M) | (45.82M) | (23.60M) | (521,576) | (1.77M) | (2.82M) | (56,734) | N/A |
| FCF / Share | -1.47 | -1.12 | -1.64 | -1.62 | -1.67 | -1.33 | -1.37 | -5.65 | -11.14 | -0.71 | N/A |
| Operating CF | (131.56M) | (79.13M) | (64.36M) | (50.14M) | (45.82M) | (23.60M) | (208,119) | (722,451) | (665,984) | (26,636) | N/A |
| Total Assets | 440.10M | 302.15M | 124.54M | 169.99M | 164.00M | 81.52M | 2.94M | 3.53M | 4.03M | 202,750 | N/A |
| Total Debt | 0 | 21.85M | 14.13M | 72,000 | 0 | 0 | 0 | 0 | 15,743 | 0 | N/A |
| Cash & Equiv | 257.84M | 273.74M | 99.70M | 142.14M | 133.54M | 80.09M | 17,931 | 154,791 | 3,977 | 10,962 | N/A |
| Book Value | 332.33M | 241.45M | 78.13M | 150.92M | 151.66M | 75.87M | 2.74M | 3.52M | 3.95M | 127,279 | N/A |
| Return on Equity | -0.55 | -0.45 | -1.23 | -0.38 | -0.61 | -0.45 | -0.41 | -0.24 | -0.31 | -1.41 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (77.10M) | (50.44M) | (67.27M) | (42.74M) | (23.35M) | (34.74M) | (13.68M) | (5.85M) | (54.40M) | (23.86M) | (17.92M) | (29.13M) |
| EPS | -0.71 | -0.51 | -0.78 | -0.50 | -0.27 | -0.41 | -0.18 | -0.08 | -1.14 | -0.59 | -0.45 | -0.76 |
| Free Cash Flow | (42.63M) | (72.54M) | (29.57M) | (29.60M) | (29.42M) | (25.35M) | (17.19M) | (19.99M) | (16.60M) | (20.56M) | (16.63M) | (13.85M) |
| FCF / Share | -0.39 | -0.81 | -0.34 | -0.35 | -0.35 | -0.30 | -0.22 | -0.28 | -0.35 | -0.51 | -0.42 | -0.36 |
| Operating CF | (42.63M) | (72.54M) | (29.57M) | (29.60M) | (29.42M) | (25.35M) | (17.19M) | (19.99M) | (16.60M) | (20.56M) | (16.63M) | (13.85M) |
| Total Assets | 401.29M | 440.10M | 236.92M | 265.09M | 275.32M | 302.15M | 319.77M | 268.14M | 275.53M | 124.54M | 141.55M | 142.09M |
| Total Debt | 40.77M | 0 | 0 | 41.19M | 22.04M | 21.85M | 24.31M | 24.25M | 14.19M | 14.13M | 14.07M | 75,000 |
| Cash & Equiv | 262.52M | 257.84M | 19.96M | 33.39M | 82.85M | 273.74M | 295.28M | 243.13M | 252.33M | 99.70M | 117.70M | 116.89M |
| Book Value | 278.85M | 332.33M | 130.60M | 185.40M | 222.81M | 241.45M | 262.19M | 202.05M | 196.06M | 78.13M | 95.98M | 105.97M |
| Return on Equity | -0.28 | -0.15 | -0.52 | -0.23 | -0.10 | -0.14 | -0.05 | -0.03 | -0.28 | -0.31 | -0.19 | -0.27 |
MNMD News
